A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors

Summary

This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor .

Timeline

Start

2024-12-17

Primary completion

2026-12

Completion

2027-12

Drugs

Indications